Lilly rides Mounjaro, Zepbound to better
Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles
Lynn Williams breaks NWSL goal
Lynn Williams scored her 79th league goal, becoming the National Women’s Soccer League all-time scor2024-05-21Xi Story: Agricultural Science, Technology Carry the Weight of Food Security
Contact Us HomeNewsHighlightACWF NewsSocietyWom2024-05-21Migrant birds seen at Hailiu reservoir in Hohhot, Inner Mongolia
Migrant birds are seen at the Hailiu reservoir in Tumd Left Banner in Hohhot, north China's Inner Mo2024-05-21This week: Retail sales, United Airlines and Netflix earnings
Retail receiptsOn Monday, the government releases its report on retail sales for the month of March.2024-05-21- A small group of NFL rookies from the 2024 class, including Caleb Williams and Drake Maye, sat down2024-05-21
View of paddy fields in Guiyang, SW China's Guizhou
Aerial Photo taken on Aug. 27, 2022 shows the view of paddy fields in Matou Village of Hefeng Townsh2024-05-21
atest comment